Maze Therapeutics

press releases archive

The information in our press releases and presentations should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.

January 10, 2022
Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
January 5, 2022
Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
March 23, 2021
Maze Therapeutics Appoints Atul Dandekar as Chief Strategy Officer and Expands Board of Directors
March 23, 2021
Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-threatening Diseases
December 7, 2020
BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
recent

want to get a hold of a representative?

Jillian Connell
Maze Therapeutics
jconnell@mazetx.com

media inquires

Katie Engleman
1AB
katie@1abmedia.com

Contact Us
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Essential Cookies

These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Powered by  GDPR Cookie Compliance